stockrowBioCardia, Inc.
BCDA Healthcare Biotechnology
BioCardia, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $477,000.00, up 722.4% from fiscal 2024.
- EPS
- +67.5%
- Free cash flow
- −5.15%
Quarter to June 2026, against a year earlier
Follow BCDA
Alert me
BioCardia, Inc. (BCDA) EV/Sales
As of 6 November 2026, BioCardia, Inc. (BCDA) trades at a EV/Sales of 28.7×. Over the past ten years it has ranged from −12.4× (October 2016) to 606× (July 2017); the current reading is higher than 38% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 39.2× | 23.82% |
| FY2024 | 31.6× | (19.84%) |
| FY2023 | 39.5× | 44.21% |
| FY2022 | 27.4× | 7.43% |
| FY2021 | 25.5× | (81.07%) |
| FY2020 | 135× | 344.83% |
| FY2019 | 30.3× | (59.23%) |
| FY2018 | 74.2× | (64.13%) |
| FY2017 | 207× | 29.85% |
| FY2016 | 159× | 3,881.39% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2024 | 23.6× | (25.98%) |
| Mar 2024 | 31.8× | (19.33%) |
| Dec 2023 | 39.5× | 69.56% |
| Sep 2023 | 23.3× | (82.34%) |
| 34 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TCRX TScan Therapeutics, Inc. compare | −6.2× |
| LPCN Lipocine Inc. compare | −1.5× |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | n/m |
| AKTX Akari Therapeutics PLC compare | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | 0.1× |
| CASIF CASI Pharmaceuticals Inc. compare | 1.8× |
| BOLT Bolt Biotherapeutics, Inc. compare | 2.5× |
| DYAI Dyadic International Inc. compare | 3.4× |
| BCDA BioCardia, Inc. | 28.7× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)